Accenture Ventures, the venture capital arm of Accenture, has invested in Turbine, a predictive simulation company developing a platform for understanding human biology. This strategic investment aims to enhance Turbine’s capabilities for global biopharma companies.
Turbine’s central technology, the Simulated Cell™ platform, leverages machine learning to decipher decision-making processes in human cells. It models molecular interactions within and around cells, enabling massive virtual experiments that reveal disease mechanisms and therapy responses.
Advanced technologies and digital capabilities are increasingly differentiating the biopharma industry, with AI playing a pivotal role in drug discovery. Turbine’s platform has proven its ability to unlock valuable biological insights for biopharma clients.
Pharmaceutical leaders collaborate with Turbine to identify promising drug targets, select patient populations for therapies, and determine optimal combination therapies. This enables the discovery of previously overlooked treatments and the early identification of potential clinical trial failures.
Petra Jantzer, global lead of Accenture’s Life Sciences business, indicated that Turbine’s platform is a significant tool for biopharma companies to unravel the complexities of biological systems, develop targeted treatments, and advance AI-based drug discovery, ultimately aiming to enhance patient therapies.
Szabolcs Nagy, co-founder and CEO of Turbine, indicated that the heterogeneity of complex diseases poses challenges for AI in drug discovery and that their Simulated Cells offer a scalable means to represent disease heterogeneity, guiding researchers toward the most effective experiments.
By leveraging Accenture’s expertise, Turbine aims to expand its market reach and enhance its simulation platform. This collaboration will contribute to the overall advancement of the biopharma industry, ensuring efficient and effective drug development.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
